Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Status:
Not yet recruiting
Trial end date:
2023-06-23
Target enrollment:
Participant gender:
Summary
Various drugs have been added to different treatment regimens in order to improve the
response rate in patients with Acute Lymphoblastic Leukemia, however, it has been shown that
adding Bortezomib to the relapsing regimen improves the proportion of second complete
remissions without increasing chemotherapy toxicity. Therefore, proteasome inhibitors can
drastically modify the prognosis of patients, since their synergy with drugs such as steroids
has positioned them as an attractive strategy.